Allergies News and Research

Latest Allergies News and Research

Approval of Diovan (valsartan) in U.S. for hypertension in children and adolescents

Diovan (valsartan), an angiotensin receptor blocker or ARB, has been approved following a priority review by the U.S. Food and Drug Administration (FDA) for the treatment of high blood pressure in children and adolescents ages six to 16.

4 Dec 2007

Inhaled immune system stimulant launches immune response in lungs to wipe out lethal infections

An inhaled immune system stimulant protects mice against lethal pneumococcal pneumonia and other deadly bacterial, viral and fungal infections of the lungs, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at a major scientific meeting.

4 Dec 2007

Merck Serono's Cyanokit approved in Europe

Merck Serono, a division of Merck KGaA, announced today that the European Commission has granted marketing authorization for its product Cyanokit (active substance: hydroxocobalamin) for the treatment of known or suspected cyanide poisoning in both adults and the pediatric population.

3 Dec 2007

Strange behaviours linked to popular sleeping pill Zolpidem

The Therapeutic Goods Administration (TGA) in Australia has updated warnings on a popular sleeping drug.

29 Nov 2007

Cholera can be controlled with oral vaccines

Endemic cholera, a potentially fatal diarrheal disease found in the world's most impoverished countries, could be effectively controlled by orally vaccinating half of the affected populations once every two years for only pennies per dose, according to new findings by an international team of researchers led by Ira M. Longini Jr., Ph.D., a biostatistician in the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center in Seattle. Longini and colleagues will report their findings online Nov. 27 in PLoS Medicine.

27 Nov 2007

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

27 Nov 2007

Electronic patient tracking technologies versus manual whiteboards

Proper design of computational tools is critical if they are to be used with success in patient-care settings, particularly in hospital emergency rooms, a field study conducted by researchers at the University at Buffalo and other institutions recently revealed.

27 Nov 2007

Saline irrigation versus saline spray for relief of chronic nasal symptoms

An inexpensive, safe and easy treatment is an effective method for treating chronic nasal and sinus symptoms – more effective, in fact, than commonly used saline sprays, according to a new study from University of Michigan Health System researchers.

20 Nov 2007

Schering-Plough acquires Organon BioSciences

Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

20 Nov 2007

Protein in mice known as RGS13 suppresses allergic reactions

A protein in mice known as RGS13 suppresses allergic reactions, including the severe, life-threatening allergic reaction known as anaphylaxis, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

20 Nov 2007

Physical therapy in intensive care reduce hospital stays

The American Physical Therapy Association (APTA) cites the results of the first study to show the effectiveness of early physical therapy for patients in a medical intensive care unit (ICU).

19 Nov 2007

Pfizer to acquire Coley Pharmaceutical Group

Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

19 Nov 2007

Progress in in food allergy prevention

Progress has been made in food allergy prevention and management according to investigators presenting the latest research at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas. Important research findings may impact diet restrictions of food allergic patients.

15 Nov 2007

STEP study of Merck's HIV vaccine to be unblinded

Merck & Co., Inc. and the HIV Vaccine Trials Network (HVTN) today announced that study volunteers in the STEP study of Merck's HIV vaccine (V520) will be told whether they received vaccine or placebo, and all study volunteers will be encouraged to continue to return to their study sites on a regular basis for ongoing risk reduction counseling and study-related tests.

14 Nov 2007

Hope on the horizon for hereditary angioedema sufferers

Although there is currently no treatment approved by the Federal Drug Administration (FDA) for acute attacks of hereditary angioedema (HAE) - a genetic disease causing swelling of extremities, face and internal organs that can be life-threatening - hope is on the horizon according to a team of experts presenting the latest research at the Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas.

14 Nov 2007

La Jolla Institute for Allergy & Immunology to perform study on allergy molecular causes

A major study that will provide a new window into understanding and potentially treating allergies will be conducted by the La Jolla Institute for Allergy & Immunology (LIAI) under a $5 million federal contract.

14 Nov 2007

Volunteers in AIDS vaccine trial may be at greater risk of infection

Following the aborting of two international trials of an experimental AIDS vaccine, thousands of volunteers have been told the vaccine may have actually raised their risk of infection.

14 Nov 2007

FDA approves new nonprescription allergy drug Zyrtec-D

The Food and Drug Administration (FDA) has approved Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg), an allergy drug, for nonprescription use in adults and children 12 years of age and older. This drug combines an antihistamine with a nasal decongestant.

13 Nov 2007

Factor key to severity of community-associated methicillin-resistant staph infections identified

Newly described proteins in drug-resistant strains of the Staphylococcus aureus bacterium attract and then destroy protective human white blood cells - a key process ensuring that S. aureus survives and causes severe disease, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

13 Nov 2007

Managing asthma

The great majority of the nearly 23 million people with asthma, including 6.5 million children, can avoid serious symptoms and disability if they follow the latest guidelines to keep their disease under control.

13 Nov 2007